Pharmacokinetic-Pharmacodynamic Target Attainment Analysis to Support VL-2397 Dose Selection for a Phase 2 Trial in Patients with Invasive Aspergillosis
2017 ◽
Vol 4
(suppl_1)
◽
pp. S473-S473
◽
Keyword(s):
Phase 2
◽
2019 ◽
Vol 74
(Supplement_3)
◽
pp. iii35-iii41
◽
2017 ◽
Vol 4
(suppl_1)
◽
pp. S530-S530
◽
Keyword(s):